-2%
Glinta Plus is prescribed as a supplementary treatment alongside diet and exercise to enhance blood sugar control in adults with type 2 diabetes mellitus. This medication belongs to the class of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors.
Linagliptin works by inhibiting the DPP-4 enzyme, which slows the breakdown of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones help regulate blood sugar by increasing insulin production and reducing glucagon levels. After food intake, incretin hormone levels rise, promoting insulin secretion and reducing glucose production in the liver.
Empagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose reabsorption in the kidneys. By inhibiting this process, Empagliflozin lowers the renal threshold for glucose, increasing glucose excretion through urine and helping reduce blood sugar levels.